Cover Image
市場調查報告書

酪胺酸蛋白激酶SYK:開發中產品分析

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 367831
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白激酶SYK:開發中產品分析 Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 104 Pages
簡介

本報告提供以酪胺酸蛋白激酶SYK為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白激酶SYK 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • AB Science SA
  • Almirall, S.A.
  • Archer Pharmaceuticals, Inc.
  • Asana BioSciences, LLC
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genosco
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Hutchison MediPharma Limited
  • Levolta Pharmaceuticals, Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Oscotec Inc.
  • Portola Pharmaceuticals, Inc.
  • Rigel Pharmaceuticals, Inc.
  • 大鵬藥品工業
  • TopiVert Ltd

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0803TDB

Summary

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 3, 12 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Ophthalmology, Gastrointestinal, Hematological Disorders, Central Nervous System, Respiratory, Cardiovascular and Genito Urinary System And Sex Hormones which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia (CLL), Allergic Conjunctivitis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Chronic Lymphocytic Leukemia (CLL), Cutaneous Lupus Erythematosus, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Relapsed Chronic Lymphocytic Leukemia (CLL), Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Allergies, Alzheimer's Disease, Anaphylactic Shock, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Urticaria Or Hives, Cutaneous T-Cell Lymphoma, Glomerulonephritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Leukemias, Lupus Erythematosus, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Small Cell Lung Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren), Skin Inflammation, Solid Tumor and Systemic Lupus Erythematosus.

Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview
    • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Almirall SA
    • Archer Pharmaceuticals Inc
    • Asana BioSciences LLC
    • Beijing Hanmi Pharmaceutical Co Ltd
    • Celgene Corp
    • Clevexel Pharma SAS
    • F. Hoffmann-La Roche Ltd
    • Fujifilm Corp
    • Genosco Inc
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • Hutchison China MediTech Ltd
    • Japan Tobacco Inc
    • Levolta Pharmaceuticals Inc
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Portola Pharmaceuticals Inc
    • Rigel Pharmaceuticals Inc
    • Taiho Pharmaceutical Co Ltd
    • TopiVert Ltd
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles
    • AB-8779 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-509 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entospletinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FF-10102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fostamatinib disodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-9876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2646264 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMPL-523 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JTE-852 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LAS-189386 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilvadipine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRT-2761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-9021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKIO-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SYK for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-659 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-5567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-1210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-1288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-1630 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-1890 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2017: Asana BioSciences Initiates Phase 2 Evaluation of ASN002, a Novel SYK/JAK Inhibitor, in NHL, CLL and MF
      • May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
      • May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
      • Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States
      • Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
      • Mar 27, 2017: Asana BioSciences To Present New Data on ASN002 at AACR 2017
      • Mar 16, 2017: Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis
      • Jan 30, 2017: Fostamatinib Study Results Continue to Trend Positive
      • Jan 10, 2017: Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
      • Dec 06, 2016: Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting
      • Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
      • Nov 28, 2016: TopiVert Receives IND Approval for TOP1630 in the Treatment of Dry Eye Syndrome
      • Nov 14, 2016: Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting
      • Nov 03, 2016: Takeda to Present Clinical Data on TAK-659 During 58th American Society of Hematology Annual Meeting
      • Oct 20, 2016: Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1)
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by AB Science SA, H1 2017
  • Pipeline by Almirall SA, H1 2017
  • Pipeline by Archer Pharmaceuticals Inc, H1 2017
  • Pipeline by Asana BioSciences LLC, H1 2017
  • Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017
  • Pipeline by Celgene Corp, H1 2017
  • Pipeline by Clevexel Pharma SAS, H1 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Pipeline by Fujifilm Corp, H1 2017
  • Pipeline by Genosco Inc, H1 2017
  • Pipeline by Gilead Sciences Inc, H1 2017
  • Pipeline by GlaxoSmithKline Plc, H1 2017
  • Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Pipeline by Japan Tobacco Inc, H1 2017
  • Pipeline by Levolta Pharmaceuticals Inc, H1 2017
  • Pipeline by Merck KGaA, H1 2017
  • Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Pipeline by Portola Pharmaceuticals Inc, H1 2017
  • Pipeline by Rigel Pharmaceuticals Inc, H1 2017
  • Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Pipeline by TopiVert Ltd, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Dormant Products, H1 2017 (Contd..2), H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
Back to Top